Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Insulin glulisine is a short-acting form of insulin used for glycemic control in type 1 and type 2 diabetes mellitus. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism.
- Mechanism
- Curator reviewed
Insulin glulisine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the arginine at position B3 for lysine and replacement of the B29 lysine with glutamic acid decreases the propensity to form hexamers, stabilizes the hormone in monomeric form and results in a rapid rate of absorption and short duration of action.
- Primary indication
- Insulin glulisine is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.Curator reviewed · 4 structured indications
- Formula / weight
- C258H384N64O78S6 · 5823.0 Da
- First approval
- Canada, 2006 · United States, 2009 · European Union, 2016
- Also known as
- Insulin Glulisine (recombinant DNA origin) · Insulin glulisine recombinant
- Code names
- HMR-1964
- Brand names
- Apidra
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Insulin glulisine, and which of those have an active Phase 3 trial?